Redcare Pharmacy's New Leadership Faces a High-Stakes Turnaround
Published on 04/15/2026 at 18:46 | Redaktion boerse-global.de
Redcare Pharmacy's stock is showing signs of life, but the path to a full recovery remains steep. The online pharmacy's shares recently climbed nearly six percent to 44.92 euros, extending a monthly gain of over 13 percent. This uptick coincides with a major leadership overhaul finalized at the company's Annual General Meeting this Wednesday, marking the most significant management change in its recent history.
The new team inherits a business showing surprising operational strength. Redcare's first-quarter figures for 2026 revealed explosive growth in its core prescription medication segment. Revenue from this division surged 55 percent to 168 million euros, a result that handily beat market expectations. Total group revenue advanced 18.3 percent to 848 million euros, supported by a growing customer base that reached 14.2 million active users by the end of March.
Central to the shareholder meeting was the official appointment of Hendrik Krampe as the new Chief Financial Officer. Krampe brings over three decades of financial experience, including an eleven-year stint at Amazon's European headquarters in Luxembourg. The supervisory board was also comprehensively renewed, with Anja Hendel, Max Müller, and Peter Schmid von Linstow replacing three outgoing members. This fresh leadership is now tasked with sustaining the recent momentum.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
Market analysts view the operational progress positively. Jefferies maintains a "Buy" rating with a price target of 150 euros, praising the strong start to the year. Deutsche Bank also recommends purchasing the stock, highlighting Redcare's increasing market share in the e-prescription segment. The company itself has reaffirmed its full-year guidance, targeting revenue growth of 13 to 15 percent for 2026 and an adjusted EBITDA margin of at least 2.5 percent.
Despite the positive quarterly data and analyst support, the stock's broader performance tells a sobering story. Since the start of the year, the share price has fallen approximately 33 percent. It currently trades worlds away from its 52-week high of 136.20 euros. A Relative Strength Index reading of 34.5 indicates the stock, despite a recent bounce, is still hovering near oversold territory following months of selling pressure.
Redcare's dominant market position provides a structural advantage that could be further bolstered by external factors. The company commands a 67 percent market share in the German prescription segment. A recent proposal from a government commission, recommending a 50 percent increase in the statutory co-payment for prescription drugs, could drive more price-sensitive patients from local pharmacies to cheaper online alternatives like Redcare.
The complete set of financials for the first quarter will be published on May 6. All eyes will be on the newly constituted board to demonstrate that the prescription revenue surge is sustainable. For now, the 50-day moving average at 49.48 euros stands as the next technical hurdle for the stock's tentative recovery.
Ad
Redcare Pharmacy Stock: New Analysis - 15 April
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
